Physician profile
Mark J Schuld
NPI 1023014479
$4,711.52
in general payments reported to CMS, 2019-2025
30 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $157 · 2021: $80.32 · 2022: $384 · 2023: $959 · 2024: $1,154 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.55 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $682.94 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $561.72 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $514.04 | 2019-2025 | |
| Lilly USA, LLC | $443.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $230.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.66 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $201.86 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.88 | 2022-2025 | |
| Exact Sciences Corporation | $142.35 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $113.32 | 2019-2023 | Steglatro, Belsomra |
| Dexcom, INC. | $107.67 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $88.55 | 2023-2025 | Repatha, Evenity, Otezla |
| Phathom Pharmaceuticals, INC. | $88.11 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $53.59 | 2019-2023 | Myrbetriq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $52.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $47.11 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.10 | 2023 | |
| Amneal Pharmaceuticals LLC | $30.21 | 2022-2023 | Unithroid |
| Antares Pharma, INC. | $26.98 | 2022-2025 | Xyosted |
| Biogen, INC. | $26.67 | 2025 | Zurzuvae |
| Sanofi-Aventis U.S. LLC | $25.86 | 2019-2022 | |
| Dynavax Technologies Corporation | $25.42 | 2024 | Heplisav-B |
| Genzyme Corporation | $20.10 | 2021 | |
| Halozyme INC | $18.56 | 2023 | |
| Abbott Laboratories | $17.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.77 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.43 | 2022 | |
| Organon LLC | $11.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schuld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.